IV 옥살 리플 라틴, 플루오로 루라실, 폴리닉 산/레우코보 린, 베바 시주 맙, 전이 대장 암을 가진 성인 참가자의 Panitumumab과 함께 Telisotuzumab adizutecan의 부작용 및 효능을 평가하는 연구 (AndroMETa-CRC)
전이성 결장 직장암이있는 대상체에서 Telisotuzumab Adizutecan과의 다중 처리 조합의 안전성 및 효능을 평가하기위한 2 상, 오픈 라벨, 무작위, 마스터 프로토콜 연구
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: ABBVIE CALL CENTER
- 전화번호: 844-663-3742
- 이메일: abbvieclinicaltrials@abbvie.com
연구 장소
-
-
-
Thessaloniki, 그리스, 54639
- 모병
- Theagenio Cancer Hospital /ID# 269640
-
-
Attica
-
Chaïdári, Attica, 그리스, 12462
- 모병
- University General Hospital Attikon /ID# 268555
-
Nea Kifissia, Attica, 그리스, 14564
- 모병
- General Oncology Hospital of Kifisia Agioi Anargyroi /ID# 268762
-
Piraeus, Attica, 그리스, 18547
- 모병
- Metropolitan Hospital /ID# 269636
-
-
Thessaloniki
-
Panórama, Thessaloniki, 그리스, 55236
- 모병
- St. Luke's Hospital /ID# 269963
-
-
-
-
-
Kaohsiung City, 대만, 807
- 모병
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 269724
-
Kaohsiung City, 대만, 833
- 모병
- Kaohsiung Chang Gung Memorial Hospital /ID# 269726
-
Tainan, 대만, 704
- 모병
- National Cheng Kung University Hospital /ID# 270835
-
Taipei, 대만, 112
- 모병
- Taipei Veterans General Hospital /ID# 269718
-
Taipei, 대만, 100
- 모병
- National Taiwan University Hospital /ID# 269717
-
Taoyuan City, 대만, 333
- 모병
- Linkou Chang Gung Memorial Hospital /ID# 269725
-
-
-
-
California
-
Duarte, California, 미국, 91010
- 모병
- City of Hope National Medical Center /ID# 270255
-
Santa Monica, California, 미국, 90404
- 모병
- UCLA - Santa Monica /ID# 270621
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06510
- 모병
- Yale New Haven Hospital /ID# 270565
-
-
Florida
-
Orlando, Florida, 미국, 32803
- 모병
- AdventHealth Orlando /ID# 270789
-
-
Georgia
-
Marietta, Georgia, 미국, 30060
- 모병
- Northwest Georgia Oncology Centers /ID# 270245
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- 모병
- University of Chicago Medical Center /ID# 271688
-
Hinsdale, Illinois, 미국, 60521
- 모병
- Hope And Healing Cancer Services /ID# 271562
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 모병
- Dana-Farber Cancer Institute /ID# 270624
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109-5000
- 모병
- University Of Michigan /ID# 270790
-
-
Missouri
-
Kansas City, Missouri, 미국, 64111
- 모병
- Saint Lukes Hospital of Kansas City /ID# 270633
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68130
- 모병
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- 모병
- University of North Carolina at Chapel Hill /ID# 267786
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45245
- 모병
- Oncology Hematology Care - Eastgate /ID# 271493
-
-
Texas
-
Austin, Texas, 미국, 78705
- 모병
- Texas Oncology - Austin Midtown /ID# 271354
-
Webster, Texas, 미국, 77598
- 모병
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- Virginia Cancer Specialists - Fairfax /ID# 271351
-
-
Washington
-
Seattle, Washington, 미국, 98109
- 모병
- University Of Washington /ID# 271298
-
-
-
-
-
São Paulo, 브라질, 04014-002
- 모병
- Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
-
São Paulo, 브라질, 01401-002
- 모병
- Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, 브라질, 41253-190
- 모병
- Hospital Sao Rafael /ID# 271681
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, 브라질, 98700-000
- 모병
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
-
-
São Paulo
-
Barretos, São Paulo, 브라질, 14784-400
- 모병
- Hospital De Amor /ID# 271874
-
São José do Rio Preto, São Paulo, 브라질, 15090-000
- 모병
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
-
-
-
-
-
Barcelona, 스페인, 08035
- 모병
- Hospital Universitario Vall de Hebron /ID# 270191
-
Madrid, 스페인, 28027
- 모병
- Clinica Universidad de Navarra - Madrid /ID# 269754
-
Madrid, 스페인, 28046
- 모병
- Hospital Universitario La Paz /ID# 269730
-
Valencia, 스페인, 46010
- 모병
- Hospital Clinico Universitario de Valencia /ID# 269805
-
-
Cantabria
-
Santander, Cantabria, 스페인, 39008
- 모병
- Hospital Universitario Marques de Valdecilla /ID# 269732
-
-
Navarre
-
Pamplona, Navarre, 스페인, 31008
- 모병
- Clinica Universidad de Navarra - Pamplona /ID# 269753
-
-
-
-
-
Manchester, 영국, M20 4BX
- 모병
- The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
-
-
Greater London
-
London, Greater London, 영국, E1 2ES
- 모병
- Barts Health NHS Trust /ID# 271189
-
-
Oxfordshire
-
Oxford, Oxfordshire, 영국, OX3 9DU
- 모병
- Oxford University Hospitals Nhs Foundation Trust /ID# 272486
-
-
Surrey
-
Sutton, Surrey, 영국, SM2 5PT
- 모병
- The Royal Marsden - Sutton /ID# 271172
-
-
West Midlands
-
Birmingham, West Midlands, 영국, B9 5SS
- 모병
- Heartlands Hospital - University Hospitals Birmingham /ID# 271178
-
-
-
-
-
Salzburg, 오스트리아, 5020
- 모병
- Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
-
Vienna, 오스트리아, 1090
- 모병
- Medizinische Universitaet Wien /ID# 268872
-
-
Styria
-
Graz, Styria, 오스트리아, 8010
- 모병
- Medizinische Universitaet Graz /ID# 268876
-
-
-
-
-
Haifa, 이스라엘, 3109601
- 모병
- Rambam Health Care Campus- Haifa /ID# 268006
-
Jerusalem, 이스라엘, 9103102
- 모병
- Shaare Zedek Medical Center /ID# 268009
-
Jerusalem, 이스라엘, 91120
- 모병
- Hadassah Medical Center-Hebrew University /ID# 268007
-
-
Central District
-
Petah Tikva, Central District, 이스라엘, 4941492
- 모병
- Rabin Medical Center. /ID# 268008
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, 이스라엘, 6423906
- 모병
- Tel Aviv Sourasky Medical Center /ID# 268010
-
-
-
-
Milano
-
Milan, Milano, 이탈리아, 20162
- 모병
- ASST Grande Ospedale Metropolitano Niguarda /ID# 269142
-
연락하다:
- Site Coordinator
- 이메일: ctu.oncologia@ospedaleniguarda.it
-
-
Napoli
-
Naples, Napoli, 이탈리아, 80138
- 모병
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 269191
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, 일본, 464-8681
- 모병
- Aichi Cancer Center /ID# 270113
-
-
Chiba
-
Kashiwa-shi, Chiba, 일본, 277-8577
- 모병
- National Cancer Center Hospital East /ID# 270114
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, 일본, 216-8511
- 모병
- St Marianna University School Of Medicine /ID# 270111
-
-
Miyagi
-
Sendai, Miyagi, 일본, 980-8574
- 모병
- Tohoku University Hospital /ID# 270966
-
-
Tokyo
-
Chuo-Ku, Tokyo, 일본, 104-0045
- 모병
- National Cancer Center Hospital /ID# 270112
-
-
-
-
-
Brno, 체코, 656 53
- 모병
- Masarykuv onkologicky ustav v Brne /ID# 268779
-
Hradec Králové, 체코, 500 05
- 모병
- Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
-
-
Praha 17
-
Prague, Praha 17, 체코, 128 00
- 모병
- Vseobecna Fakultni nemocnice v Praze /ID# 268775
-
-
Praha 5
-
Prague, Praha 5, 체코, 150 06
- 모병
- Fakultni nemocnice Motol a Homolka /ID# 268776
-
-
Praha, Hlavni Mesto
-
Prague, Praha, Hlavni Mesto, 체코, 140 59
- 모병
- Fakultni Thomayerova nemocnice /ID# 269632
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 5G2
- 모병
- Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
-
Edmonton, Alberta, 캐나다, T6G 1Z2
- 모병
- Cross Cancer Institute. /ID# 272711
-
-
Ontario
-
London, Ontario, 캐나다, N6A 5W9
- 모병
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
-
Toronto, Ontario, 캐나다, M5G 2M9
- 모병
- Princess Margaret Cancer Centre /ID# 268715
-
-
Quebec
-
Montreal, Quebec, 캐나다, H1T 2M4
- 모병
- Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
-
-
-
-
-
Rio Piedras, 푸에르토 리코, 00935
- 모병
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268809
-
San Juan, 푸에르토 리코, 00917-5022
- 모병
- Puerto Rico Medical Research Center /ID# 268825
-
-
-
-
-
Paris, 프랑스, 75015
- 모병
- Hopital Europeen Georges Pompidou /ID# 270224
-
-
Hauts-de-France
-
Lille, Hauts-de-France, 프랑스, 59037
- 모병
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez /ID# 270222
-
-
New Aquitaine
-
Poitiers, New Aquitaine, 프랑스, 86021
- 모병
- Centre Hospitalier Universitaire de Poitiers /ID# 270225
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, 프랑스, 44000
- 모병
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 270221
-
-
Île-de-France Region
-
Paris, Île-de-France Region, 프랑스, 75013
- 모병
- Hopital Pitie Salpetriere /ID# 270220
-
-
-
-
New South Wales
-
Sydney, New South Wales, 호주, 2109
- 모병
- Macquarie University /ID# 271514
-
-
Queensland
-
South Brisbane, Queensland, 호주, 4101
- 모병
- Mater Misericordiae /ID# 270694
-
연락하다:
- Site Coordinator
- 전화번호: +61731632341
-
-
South Australia
-
Woodville South, South Australia, 호주, 5011
- 모병
- The Queen Elizabeth Hospital /ID# 270693
-
-
Victoria
-
Heidelberg, Victoria, 호주, 3084
- 모병
- Austin Health /ID# 270692
-
-
Western Australia
-
Nedlands, Western Australia, 호주, 6009
- 모병
- One Clinical Research /ID# 270695
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Laboratory values meeting the criteria within the protocol.
- Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Exclusion Criteria:
- Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
- History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Substudy 1: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
실험적: Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
실험적: Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
실험적: Substudy 1: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
실험적: Substudy 2: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
실험적: Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
실험적: Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
실험적: Substudy 2: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and panitumumab as part of the approximately 6 year study duration. |
IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection IV Infusion |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.
기간: Up to 24 Weeks
|
OR is defined as confirmed CR or PR as assessed by the investigator per RECIST, version 1.1. |
Up to 24 Weeks
|
|
Number of Participants with Adverse Events (AE)s
기간: Up to Approximately 6 Years
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 6 Years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by the Investigator
기간: Up to 22 Months
|
PFS is defined as the time from the first dose of study treatment to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by the investigator or death from any cause, whichever occurs earlier. |
Up to 22 Months
|
|
Duration of Response (DOR) as Assessed by the investigator
기간: Up to 14 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first. |
Up to 14 Months
|
|
Overall Survival (OS)
기간: Up to Approximately 6 Years
|
OS is defined as the time from first dose of study treatment to the event of death from any cause. |
Up to Approximately 6 Years
|
|
Disease Control (DC) as Assessed by the Investigator
기간: Up to Approximately 6 Years
|
DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by the investigator. |
Up to Approximately 6 Years
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: ABBVIE INC., AbbVie
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 부위별 신생물
- 신생물
- 장 질환
- 위장관 신생물
- 소화계 신생물
- 소화기계 질환
- 위장병
- 장 신생물
- 직장 질환
- 결장 질환
- 대장 신생물
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 효소 및 코엔자임
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 조정 복합체
- 피리 미딘
- Formyltetrahydrofolates
- 테트라 하이드로 폴 레이트
- 엽산
- Pterins
- Teridines
- 우라실
- 피리 미디 논
- 코엔자임
- 옥살리플라틴
- 베바시주맙
- 파니투무맙
- 플루오로우라실
- 류코보린
기타 연구 ID 번호
기타 연구 ID 번호
- M24-533
- EU CT (기타 식별자: 2024-512981-33-00)
- 2024-512981-33-00 (씨티스)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 공유 기간
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 공유 액세스 기준
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .